Thyroid functional disease: An under-recognized cardiovascular risk factor in kidney disease patients

Nephrology Dialysis Transplantation

Volumn 30, Issue 5, 2015, Pages 724-737

  Rhee, Connie M ^a   Brent, Gregory A ^b,c   Kovesdy, Csaba P ^d,e   Soldin, Offie P ^f   Nguyen, Danh ^g   Budoff, Matthew J ^h   Brunelli, Steven M ^i,j   Kalantar Zadeh, Kamyar ^a,g,k  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^f GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h HARBOR UCLA MEDICAL CENTER   (United States)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^j DAVITA CLINICAL RESEARCH   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

cardiovascular risk; hyperthyrotropinemia; hypothyroidism; renal failure; thyroid functional disease

Indexed keywords

3,3',5' TRIIODOTHYRONINE; ERYTHROPOIETIN; LIOTHYRONINE; THYROTROPIN; THYROXINE;

ANEMIA; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING DISORDER; BLOOD VESSEL CALCIFICATION; BLOOD VOLUME; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DIASTOLIC DYSFUNCTION; DYSLIPIDEMIA; END STAGE RENAL DISEASE; ENDOTHELIUM; FREE THYROXINE INDEX; HEART VENTRICLE ARRHYTHMIA; HEMODYNAMICS; HORMONAL REGULATION; HORMONE SUBSTITUTION; HORMONE TRANSPORT; HUMAN; HYPOTHYROIDISM; INFLAMMATION; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; SYSTOLIC DYSFUNCTION; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM; THYROID FUNCTION TEST; THYROID HORMONE METABOLISM; THYROID HORMONE SYNTHESIS; VASCULAR RESISTANCE; ANIMAL; BLOOD; CARDIOVASCULAR DISEASES; CHRONIC KIDNEY FAILURE; COMORBIDITY; COMPLICATION; KIDNEY; PATHOPHYSIOLOGY; RISK FACTOR; THYROID DISEASES;

ANIMALS; CARDIOVASCULAR DISEASES; COMORBIDITY; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOTHYROIDISM; KIDNEY; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; THYROID DISEASES; THYROTROPIN; TRIIODOTHYRONINE;

EID: 84929581282     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu024     Document Type: Article

References (189)

1. Bando Y, Ushiogi Y, Okafuji K et al. Non-autoimmune primary hypothyroidism in diabetic and non-diabetic chronic renal dysfunction. Exp Clin Endocrinol Diabetes 2002; 110: 408-415
2. Chonchol M, Lippi G, Salvagno G et al. Prevalence of subclinical hypothyroidism in patients with chronic kidney disease. Clin J Am Soc Nephrol 2008; 3: 1296-1300
3. Kaptein EM. Thyroid hormone metabolism and thyroid diseases in chronic renal failure. Endocr Rev 1996; 17: 45-63
4. Kaptein EM, Quion-Verde H, Chooljian CJ et al. The thyroid in endstage renal disease. Medicine 1988; 67: 187-197
5. Kutlay S, Atli T, Koseogullari O et al. Thyroid disorders in hemodialysis patients in an iodine-deficient community. Artif Organs 2005; 29: 329-332
6. Lin CC, Chen TW, Ng YY et al. Thyroid dysfunction and nodular goiter in hemodialysis and peritoneal dialysis patients. Perit Dial Int 1998; 18: 516-521
7. Lo JC, Chertow GM, Go AS et al. Increased prevalence of subclinical and clinical hypothyroidism in persons with chronic kidney disease. Kidney Int 2005; 67: 1047-1052
8. Ng YY, Wu SC, Da Lin H et al. Prevalence of clinical and subclinical thyroid disease in a peritoneal dialysis population. Perit Dial Int 2012; 32: 86-93
9. Shantha GP, Kumar AA, Bhise V et al. Prevalence of subclinical hypothyroidism in patients with end-stage renal disease and the role of serum albumin: A cross-sectional study from South India. Cardiorenal Med 2011; 1: 255-260
10. Targher G, Chonchol M, Zoppini G et al. Prevalence of thyroid autoimmunity and subclinical hypothyroidism in persons with chronic kidney disease not requiring chronic dialysis. Clin Chem Lab Med 2009; 47: 1367-1371
11. Brough R, Jones C. Iatrogenic iodine as a cause of hypothyroidism in infants with end-stage renal failure. Pediatr Nephrol 2006; 21: 400-402
12. Gavin LA, Eitan NF, Cavalieri RR et al. Hypothyroidism induced by continuous ambulatory peritoneal dialysis. West J Med 1983; 138: 562-565
13. Kerr DJ, Singh VK, Tsakiris D et al. Serum and peritoneal dialysate thyroid hormone levels in patients on continuous ambulatory peritoneal dialysis. Nephron 1986; 43: 164-168
14. Mariani LH, Berns JS. The renal manifestations of thyroid disease. J Am Soc Nephrol 2012; 23: 22-26
15. Sanai T, Inoue T, Okamura K et al. Reversible primary hypothyroidism in Japanese patients undergoing maintenance hemodialysis. Clin Nephrol 2008; 69: 107-113
16. Schomburg L. Selenium, selenoproteins and the thyroid gland: interactions in health and disease. Nat Rev Endocrinol 2012; 8: 160-171
17. Wiederkehr MR, Kalogiros J, Krapf R. Correction of metabolic acidosis improves thyroid and growth hormone axes in haemodialysis patients. Nephrol Dial Transpl 2004; 19: 1190-1197
18. Basu G, Mohapatra A. Interactions between thyroid disorders and kidney disease. Indian J Endocrinol Metab 2012; 16: 204-213
19. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev 2008; 29: 76-131
20. Cini G, Carpi A, Mechanick J et al. Thyroid hormones and the cardiovascular system: pathophysiology and interventions. Biomed Pharmacother 2009; 63: 742-753
21. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001; 344: 501-509
22. Wheeler DC, Haynes R, Landray MJ et al. Cardiovascular aspects of kidney disease. In: Taal MW, Chertow GM, Marsden PA, Skorecki K, Yu AS, Brenner BM (eds). Taal: Brenner and Rector's The Kidney. 9th edn. Philadelphia, PA: Elsevier Saunders, 2012, pp. 2060-2075
23. Carrero JJ, Qureshi AR, Axelsson J et al. Clinical and biochemical implications of low thyroid hormone levels (total and free forms) in euthyroid patients with chronic kidney disease. J Intern Med 2007; 262: 690-701
24. Enia G, Panuccio V, Cutrupi S et al. Subclinical hypothyroidism is linked to micro-inflammation and predicts death in continuous ambulatory peritoneal dialysis. Nephrol Dial Transpl 2007; 22: 538-544
25. Horacek J, Dusilova Sulkova S, Kubisova M et al. Thyroid hormone abnormalities in haemodialyzed patients: low triiodothyronine as well as high reverse triiodothyronine are associated with increased mortality. Physiol Res 2012; 61: 495-501
26. Jaroszynski AJ, Glowniak A, Chrapko B et al. Low-T3 syndrome and signal-averaged ECG in haemodialysed patients. Physiol Res 2005; 54: 521-526
27. Kang EW, Nam JY, Yoo TH et al. Clinical implications of subclinical hypothyroidism in continuous ambulatory peritoneal dialysis patients. Am J Nephrol 2008; 28: 908-913
28. Meuwese CL, Dekker FW, Lindholm B et al. Baseline levels and trimestral variation of triiodothyronine and thyroxine and their association with mortality in maintenance hemodialysis patients. Clin J Am Soc Nephrol 2012; 7: 131-138
29. Saito O, Saito T, Ueno K et al. Comparison between serum free triiodothyronine levels and body fluid distribution in hemodialysis patients. Clin Exp Nephrol 2012; 16: 952-958
30. Tatar E, Kircelli F, Asci G et al. Associations of triiodothyronine levels with carotid atherosclerosis and arterial stiffness in hemodialysis patients. Clin J Am Soc Nephrol 2011; 6: 2240-2246
31. Tatar E, Sezis Demirci M, Kircelli F et al. The association between thyroid hormones and arterial stiffness in peritoneal dialysis patients. Int Urol Nephrol 2012; 44: 601-606
32. Yang JW, Han ST, Song SH et al. Serum T3 level can predict cardiovascular events and all-cause mortality rates in CKD patients with proteinuria. Ren Fail 2012; 34: 364-372
33. Yilmaz MI, Sonmez A, Karaman M et al. Low triiodothyronine alters flow-mediated vasodilatation in advanced nondiabetic kidney disease. Am J Nephrol 2011; 33: 25-32
34. Zoccali C, Benedetto F, Mallamaci F et al. Low triiodothyronine and cardiomyopathy in patients with end-stage renal disease. J Hypertens 2006; 24: 2039-2046
35. Zoccali C, Mallamaci F, Tripepi G et al. Low triiodothyronine and survival in end-stage renal disease. Kidney Int 2006; 70: 523-528
36. Canaris GJ, Manowitz NR, Mayor G et al. The Colorado thyroid disease prevalence study. Arch Intern Med 2000; 160: 526-534
37. Hollowell JG, Staehling NW, Flanders WD et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87: 489-499
38. Ladenson PW. Diagnosis of hypothyroidism. In: Braverman LE, Cooper DS (eds). Werner and Ingbar's The Thyroid. 10th edn. Philadelphia, PA: LippincottWilliams andWilkins, 2013, pp. 606-611
39. Rhee CM, Alexander EK, Bhan I et al. Hypothyroidism and mortality among dialysis patients. Clin J Am Soc Nephrol 2013; 8: 593-601
40. Gopinath B, Harris DC, Wall JR et al. Relationship between thyroid dysfunction and chronic kidney disease in community-dwelling older adults. Maturitas. 2013; 75: 159-164
41. Sun MT, Hsiao FC, Su SC et al. Thyrotropin as an independent factor of renal function and chronic kidney disease in normoglycemic euthyroid adults. Endocr Res 2012; 37: 110-116
42. Sawant SU, Chandran S, Almeida AF et al. Correlation between oxidative stress and thyroid function in patients with nephrotic syndrome. Int J Nephrol 2011; 2011: 256420
43. Fonseca TL, Correa-Medina M, Campos MP et al. Coordination of hypothalamic and pituitary T3 production regulates TSH expression. J Clin Invest 2013; 123: 1492-1500
44. Gereben B, Zavacki AM, Ribich S et al. Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling. Endocr Rev 2008; 29: 898-938
45. Bianco AC, Salvatore D, Gereben B et al. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev 2002; 23: 38-89
46. Langton JE, Brent GA. Nonthyroidal illness syndrome: evaluation of thyroid function in sick patients. Endocrinol Metab Clin North Am 2002; 31: 159-172
47. Carrero JJ, Stenvinkel P, Lindholm B. Endocrine aspects of chronic kidney disease. In: Taal MW, Chertow GM, Marsden PA, Skorecki K, Yu AS, Brenner BM (eds). Taal: Brenner and Rector's The Kidney. 9th edn. Philadelphia, PA: Elsevier Saunders, 2012, pp. 2122-2137
48. Song SH, Kwak IS, Lee DWet al. The prevalence of low triiodothyronine according to the stage of chronic kidney disease in subjects with a normal thyroid-stimulating hormone. Nephrol Dial Transpl 2009; 24: 1534-1538
49. Iglesias P, Olea T, Vega-Cabrera C et al. Thyroid function tests in acute kidney injury. J Nephrol 2013; 26: 164-172
50. Chopra IJ, Williams DE, Orgiazzi J et al. Opposite effects of dexamethasone on serum concentrations of 3,30,50-triiodothyronine (reverse T3) and 3,305-triiodothyronine (T3). J Clin Endocrinol Metab 1975; 41: 911-920
51. Lim VS, Passo C, Murata Y et al. Reduced triiodothyronine content in liver but not pituitary of the uremic rat model: demonstration of changes compatible with thyroid hormone deficiency in liver only. Endocrinology 1984; 114: 280-286
52. Van der Poll T, Romijn JA, Endert E et al. Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans. Am J Physiol 1991; 261(4 Pt 1): E457-E465
53. Abo-Zenah HA, Shoeb SA, Sabry AA et al. Relating circulating thyroid hormone concentrations to serum interleukins-6 and-10 in association with non-thyroidal illnesses including chronic renal insufficiency. BMC Endocr Disord 2008; 8: 1
54. Zeraati AA, Layegh P, Famili Y et al. Serum triiodothyronine level as an indicator of inflammation in patients undergoing dialysis. Iran J Kidney Dis 2011; 5: 38-44
55. Soldin OP. Measuring serum thyroid-stimulating hormone, thyroid hormones, thyroid-directed antibodies, and transport proteins. In: Braverman LE, Cooper DS (eds). Werner and Ingbar's The Thyroid. 10th edn. Philadelphia, PA: Lippincott Williams and Wilkins, 2013, pp. 279-297
56. Soldin OP, Soldin SJ. Thyroid hormone testing by tandem mass spectrometry. Clin Biochem 2011; 44: 89-94
57. Soldin SJ, Soukhova N, Janicic N et al. The measurement of free thyroxine by isotope dilution tandem mass spectrometry. Clin Chim Acta 2005; 358: 113-118
58. Jonklaas J, Kahric-Janicic N, Soldin OP et al. Correlations of free thyroid hormones measured by tandem mass spectrometry and immunoassay with thyroid-stimulating hormone across 4 patient populations. Clin Chem 2009; 55: 1380-1388
59. Jonklaas J, Soldin SJ. Tandem mass spectrometry as a novel tool for elucidating pituitary-thyroid relationships. Thyroid 2008; 18: 1303-1311
60. Soldin SJ, Kahric-Janicic N, Jonklaas J et al. Comments on the manuscript by Anckaert et al. Clin Chim Acta 2010; 411: 1348-53.
61. Clin Chim Acta 2011; 412: 483. author reply 484
62. van Deventer HE, Mendu DR, Remaley AT et al. Inverse log-linear relationship between thyroid-stimulating hormone and free thyroxine measured by direct analog immunoassay and tandem mass spectrometry. Clin Chem 2011; 57: 122-127
63. Wiersinga WM, van den Berghe G. Nonthyroidal illness. In: Braverman LE, Cooper DS (eds). Werner and Ingbar's The Thyroid. 10th edn. Philadelphia, PA: LippincottWilliams andWilkins, 2013, pp. 203-217
64. Spector DA, Davis PJ, Helderman JH et al. Thyroid function and metabolic state in chronic renal failure. Ann Intern Med 1976; 85: 724-730
65. Brent GA. Mechanisms of thyroid hormone action. J Clin Invest 2012; 122: 3035-3043
66. Maia AL, Kim BW, Huang SA et al. Type 2 iodothyronine deiodinase is the major source of plasma T3 in euthyroid humans. J Clin Invest 2005; 115: 2524-2533
67. Lim CF, Bernard BF, de Jong M et al. A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia. J Clin Endocrinol Metab 1993; 76: 318-324
68. Santos GM, Pantoja CJ, Costa ESA et al. Thyroid hormone receptor binding to DNA and T3-dependent transcriptional activation are inhibited by uremic toxins. Nucl Recept 2005; 3: 1
69. Klein I, Danzi S. Thyroid disease and the heart. Circulation 2007; 116: 1725-1735
70. Danzi S, Klein I. Thyroid hormone and the cardiovascular system. Med Clin North Am 2012; 96: 257-268
71. Chen WJ, Lin KH, Lee YS. Molecular characterization of myocardial fibrosis during hypothyroidism: evidence for negative regulation of the pro-alpha1(I) collagen gene expression by thyroid hormone receptor. Mol Cell Endocrinol 2000; 162: 45-55
72. Yao J, Eghbali M. Decreased collagen gene expression and absence of fibrosis in thyroid hormone-induced myocardial hypertrophy. Response of cardiac fibroblasts to thyroid hormone in vitro. Circ Res 1992; 71: 831-839
73. Vargas F, Moreno JM, Rodriguez-Gomez I et al. Vascular and renal function in experimental thyroid disorders. Eur J Endocrinol 2006; 154: 197-212
74. Danzi S, Klein I. Thyroid hormone and the cardiovascular system. Minerva Endocrinol 2004; 29: 139-150
75. Gencer B, Collet TH, Virgini V et al. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. Circulation 2012; 126: 1040-1049
76. Rodondi N, Newman AB, Vittinghoff E et al. Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. Arch Intern Med 2005; 165: 2460-2466
77. Duntas LH. Thyroid disease and lipids. Thyroid 2002; 12: 287-293
78. Evered DC, Ormston BJ, Smith PA et al. Grades of hypothyroidism. Br Med J 1973; 1: 657-662
79. Staub JJ, Althaus BU, Engler H et al. Spectrum of subclinical and overt hypothyroidism: effect on thyrotropin, prolactin, and thyroid reserve, and metabolic impact on peripheral target tissues. Am J Med 1992; 92: 631-642
80. Drover VA, Agellon LB. Regulation of the human cholesterol 7alpha-hydroxylase gene (CYP7A1) by thyroid hormone in transgenic mice. Endocrinology 2004; 145: 574-581
81. Thompson GR, Soutar AK, Spengel FA et al. Defects of receptormediated low density lipoprotein catabolism in homozygous familial hypercholesterolemia and hypothyroidism in vivo. Proc Natl Acad Sci USA 1981; 78: 2591-2595
82. Hak AE, Pols HA, Visser TJ et al. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: The Rotterdam Study. Ann InternMed 2000; 132: 270-278
83. Imaizumi M, Akahoshi M, Ichimaru S et al. Risk for ischemic heart disease and all-cause mortality in subclinical hypothyroidism. J Clin Endocrinol Metabol 2004; 89: 3365-3370
84. Walsh JP, Bremner AP, Bulsara MK et al. Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch Intern Med 2005; 165: 2467-2472
85. Cappola AR, Fried LP, Arnold AM et al. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA 2006; 295: 1033-1041
86. Rodondi N, den Elzen WP, Bauer DC et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA 2010; 304: 1365-1374
87. Ojamaa K, Sabet A, Kenessey A et al. Regulation of rat cardiac Kv1.5 gene expression by thyroid hormone is rapid and chamber specific. Endocrinology 1999; 140: 3170-3176
88. Kweon KH, Park BH, Cho CG. The effects of L-thyroxine treatment on QT dispersion in primary hypothyroidism. J Korean Med Sci 2007; 22: 114-116
89. Unal O, Erturk E, Ozkan H et al. Effect of levothyroxine treatment on QT dispersion in patients with subclinical hypothyroidism. Endocr Pract 2007; 13: 711-715
90. Thvilum M, Brandt F, Brix TH et al. A review of the evidence for and against increased mortality in hypothyroidism. Nat Rev Endocrinol 2012; 8: 417-424
91. Haentjens P, Van Meerhaeghe A, Poppe K et al. Subclinical thyroid dysfunction and mortality: an estimate of relative and absolute excess allcause mortality based on time-to-event data from cohort studies. Eur J Endocrinol 2008; 159: 329-341
92. Ochs N, Auer R, Bauer DC et al. Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med 2008; 148: 832-845
93. Sgarbi JA, Matsumura LK, Kasamatsu TS et al: Subclinical thyroid dysfunctions are independent risk factors for mortality in a 75-year follow-up: The Japanese-Brazilian thyroid study. Eur J Endocrinol 2010; 162: 569-577
94. Iervasi G, Molinaro S, Landi P et al. Association between increased mortality and mild thyroid dysfunction in cardiac patients. Arch Intern Med 2007; 167: 1526-1532
95. McQuade C, Skugor M, Brennan DM et al. Hypothyroidism and moderate subclinical hypothyroidism are associated with increased all-cause mortality independent of coronary heart disease risk factors: A PreCIS database study. Thyroid 2011; 21: 837-843
96. Molinaro S, Iervasi G, Lorenzoni V et al. Persistence of mortality risk in patients with acute cardiac diseases and mild thyroid dysfunction. Am J Med Sci 2012; 343: 65-70
97. Rhee CM, Curhan GC, Alexander EK et al. Subclinical hypothyroidism and survival: The effects of heart failure and race. J Clin Endocrinol Metabol 2013; 98: 2326-2336
98. Foley RN, Parfrey PS, Harnett JD et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995; 47: 186-192
99. Vonend O, Rump LC, Ritz E. Sympathetic overactivity-The Cinderella of cardiovascular risk factors in dialysis patients. Semin Dial 2008; 21: 326-330
100. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305
101. Keough-Ryan TM, Kiberd BA, Dipchand CS et al. Outcomes of acute coronary syndrome in a large Canadian cohort: impact of chronic renal insufficiency, cardiac interventions, and anemia. Am J Kidney Dis 2005; 46: 845-855
102. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: The USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 2005; 16: 1788-1793
103. Iglesias P, Diez JJ. Thyroid dysfunction and kidney disease. Eur J Endocrinol 2009; 160: 503-515
104. Singer MA. Of mice and men and elephants: metabolic rate sets glomerular filtration rate. Am J Kidney Dis 2001; 37: 164-178
105. Ichihara A, Kobori H, Miyashita Y et al. Differential effects of thyroid hormone on renin secretion, content, and mRNA in juxtaglomerular cells. Am J Physiol 1998; 274(2 Pt 1): E224-E231
106. Vargas F, Rodriguez-Gomez I, Vargas-Tendero P et al. The reninangiotensin system in thyroid disorders and its role in cardiovascular and renal manifestations. J Endocrinol 2012; 213: 25-36
107. Bradley SE, Stephan F, Coelho JB et al. The thyroid and the kidney. Kidney Int 1974; 6: 346-365
108. Falk SA, Buric V, Hammond WS et al. Serial glomerular and tubular dynamics in thyroidectomized rats with remnant kidneys. Am J Kidney Dis 1991; 17: 218-227
109. Hataya Y, Igarashi S, Yamashita T et al. Thyroid hormone replacement therapy for primary hypothyroidism leads to significant improvement of renal function in chronic kidney disease patients. Clin Exp Nephrol 2013; 17: 525-531
110. Karanikas G, Schutz M, Szabo M et al. Isotopic renal function studies in severe hypothyroidism and after thyroid hormone replacement therapy. Am J Nephrol 2004; 24: 41-45
111. Kreisman SH, Hennessey JV. Consistent reversible elevations of serum creatinine levels in severe hypothyroidism. Arch Intern Med 1999; 159: 79-82
112. Villabona C, Sahun M, Roca M et al. Blood volumes and renal function in overt and subclinical primary hypothyroidism. Am J Med Sci 1999; 318: 277-280
113. Shin DH, Lee MJ, Kim SJ et al. Preservation of renal function by thyroid hormone replacement therapy in chronic kidney disease patients with subclinical hypothyroidism. J Clin Endocrinol Metab 2012; 97: 2732-2740
114. Shin DH, Lee MJ, Lee HS et al. Thyroid hormone replacement therapy attenuates the decline of renal function in chronic kidney disease patients with subclinical hypothyroidism. Thyroid 2013; 23: 654-661
115. Bentley AG, Madsen KM, Davis RG et al. Response of the medullary thick ascending limb to hypothyroidism in the rat. Am J Pathol 1985; 120: 215-221
116. Bradley SE, Coelho JB, Sealey JE et al. Changes in glomerulotubular dimensions, single nephron glomerular filtration rates and the reninangiotensin system in hypothyroid rats. Life Sci 1982; 30: 633-639
117. Wheatley T, Edwards OM. Mild hypothyroidism and oedema: evidence for increased capillary permeability to protein. Clin Endocrinol 1983; 18: 627-635
118. Rodriguez-Gomez I, Banegas I,Wangensteen R et al. Influence of thyroid state on cardiac and renal capillary density and glomerular morphology in rats. J Endocrinol 2013; 216: 43-51
119. Raggi P, Boulay A, Chasan-Taber S et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002; 39: 695-701
120. Shantouf RS, Budoff MJ, Ahmadi N et al. Total and individual coronary artery calcium scores as independent predictors of mortality in hemodialysis patients. Am J Nephrol 2010; 31: 419-425
121. Sato Y, Nakamura R, Satoh M et al. Thyroid hormone targets matrix Gla protein gene associated with vascular smooth muscle calcification. Circ Res 2005; 97: 550-557
122. Mizuno I, Takahashi Y, Okimura Y et al. Upregulation of the klotho gene expression by thyroid hormone and during adipose differentiation in 3T3-L1 adipocytes. Life Sci 2001; 68: 2917-2923
123. Bucay N, Sarosi I, Dunstan CR et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12: 1260-1268
124. Dhore CR, Cleutjens JP, Lutgens E et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001; 21: 1998-2003
125. Jono S, Ikari Y, Shioi A et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002; 106: 1192-1194
126. Kiechl S, Schett G, Wenning G et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004; 109: 2175-2180
127. Nagasaki T, Inaba M, Jono S et al. Increased levels of serum osteoprotegerin in hypothyroid patients and its normalization with restoration of normal thyroid function. Eur J Endocrinol 2005; 152: 347-353
128. Dorr M, Ruppert J, Wallaschofski H et al. The association of thyroid function and heart valve sclerosis. Results from a population-based study. Endocr J 2008; 55: 495-502
129. Kim ES, Shin JA, Moon S et al. Association between low serum free thyroxine concentrations and coronary artery calcification in healthy euthyroid subjects. Thyroid 2012; 22: 870-876
130. Singh AK. What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level? Curr Opin Nephrol Hypertens 2010; 19: 420-424
131. Szczech LA, Barnhart HX, Inrig JK et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008; 74: 791-798
132. Chadarevian R, Bruckert E, Leenhardt L et al. Components of the fibrinolytic system are differently altered in moderate and severe hypothyroidism. J Clin Endocrinol Metab 2001; 86: 732-737
133. Cinemre H, Bilir C, Gokosmanoglu F et al. Hematologic effects of levothyroxine in iron-deficient subclinical hypothyroid patients: A randomized, double-blind, controlled study. J Clin Endocrinol Metab 2009; 94: 151-156
134. Donati RM, Fletcher JW,Warnecke MA et al. Erythropoiesis in hypothyroidism. Proc Soc Exp Biol Med 1973; 144: 78-82
135. Fein HG, Rivlin RS. Anemia in thyroid diseases. Med Clin North Am 1975; 59: 1133-1145
136. Mehmet E, Aybike K, Ganidagli S et al. Characteristics of anemia in subclinical and overt hypothyroid patients. Endocr J 2012; 59: 213-220
137. Ng YY, Lin HD, Wu SC et al. Impact of thyroid dysfunction on erythropoietin dosage in hemodialysis patients. Thyroid 2012; 23: 552-561
138. Chang PM, Ng YY. Amiodarone-induced hypothyroidism with EPO-resistant anemia in a patient with chronic renal failure. J Chin Med Assoc 2008; 71: 576-578
139. Dilek M, Akpolat T, Cengiz K. Hypothyroidism as a cause of resistance to erythropoietin. Nephron 2002; 92: 248
140. Sungur C, Erbas T, Akpolat T et al. Resistance to human recombinant erythropoietin in hypothyroidism. Acta Haematol 1992; 88: 162
141. Touam M, Guery B, Goupy C et al. Hypothyroidism and resistance to human recombinant erythropoietin. Nephrol Dial Transpl 2004; 19: 1020-1021
142. Angiolillo DJ, Bernardo E, Sabate M et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2007; 50: 1541-1547
143. Gurbel PA. The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor. Rev Cardiovasc Med 2006; 7(Suppl 4): S20-S28
144. Masunaga R, Nagasaka A, Nakai A et al. Alteration of platelet aggregation in patients with thyroid disorders. Metabolism 1997; 46: 1128-1131
145. Edson JR, Fecher DR, Doe RP. Low platelet adhesiveness and other hemostatic abnormalities in hypothyroidism. Ann Intern Med 1975; 82: 342-346
146. Coban E, Yazicioglu G, Ozdogan M. Platelet activation in subjects with subclinical hypothyroidism. Med Sci Monit 2007; 13: CR211-CR214
147. Kim JH, Park JH, Kim SY et al. The mean platelet volume is positively correlated with serum thyrotropin concentrations in a population of healthy subjects and subjects with unsuspected subclinical hypothyroidism. Thyroid 2013; 23: 31-37
148. Yilmaz H, Ertugrul O, Ertugrul B et al. Mean platelet volume in patients with subclinical hypothyroidism. Platelets 2011; 22: 143-147
149. Bath P, Algert C, Chapman N et al. Association of mean platelet volume with risk of stroke among 3134 individuals with history of cerebrovascular disease. Stroke 2004; 35: 622-626
150. Endler G, Klimesch A, Sunder-Plassmann H et al. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol 2002; 117: 399-404
151. Vizioli L, Muscari S, Muscari A. The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases. Int J Clin Pract 2009; 63: 1509-1515
152. Franchini M, Veneri D, Lippi G. Analysis of thyroid hormone status in 131 consecutive individuals with low von Willebrand factor levels. Thromb Haemost 2005; 93: 392-393
153. Muller B, Tsakiris DA, Roth CB et al. Haemostatic profile in hypothyroidism as potential risk factor for vascular or thrombotic disease. Eur J Clin Invest 2001; 31: 131-137
154. Nordoy A, Vik-Mo H, Berntsen H. Haemostatic and lipid abnormalities in hypothyroidism. Scand J Haematol 1976; 16: 154-160
155. Simone JV, Abildgaard CF, Schulman I. Blood coagulation in thyroid dysfunction. N Engl J Med 1965; 273: 1057-1061
156. Squizzato A, Gerdes VE, AgenoWet al. The coagulation system in endocrine disorders: A narrative review. Intern Emerg Med 2007; 2: 76-83
157. Menon V, Wang X, Greene T et al. Relationship between C-reactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease. Am J Kidney Dis 2003; 42: 44-52
158. Ridker PM, Cushman M, Stampfer MJ et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-979
159. Ridker PM, Hennekens CH, Buring JE et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843
160. Boelen A, Kwakkel J, Wiersinga WM et al. Chronic local inflammation in mice results in decreased TRH and type 3 deiodinase mRNA expression in the hypothalamic paraventricular nucleus independently of diminished food intake. J Endocrinol 2006; 191: 707-714
161. Torpy DJ, Tsigos C, Lotsikas AJ et al. Acute and delayed effects of a single-dose injection of interleukin-6 on thyroid function in healthy humans. Metabolism 1998; 47: 1289-1293
162. Christ-Crain M, Meier C, Guglielmetti M et al. Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trial. Atherosclerosis 2003; 166: 379-386
163. Hueston WJ, King DE, Geesey ME. Serum biomarkers for cardiovascular inflammation in subclinical hypothyroidism. Clin Endocrinol 2005; 63: 582-587
164. Kvetny J, Heldgaard PE, Bladbjerg EM et al. Subclinical hypothyroidism is associated with a low-grade inflammation, increased triglyceride levels and predicts cardiovascular disease in males below 50 years. Clin Endocrinol 2004; 61: 232-238
165. Tuzcu A, Bahceci M, Gokalp D et al. Subclinical hypothyroidism may be associated with elevated high-sensitive C-reactive protein (low grade inflammation) and fasting hyperinsulinemia. Endocr J 2005; 52: 89-94
166. Lim VS. Thyroid function in patients with chronic renal failure. Am J Kidney Dis 2001; 38(4 Suppl 1): S80-S84
167. Meuwese CL, Carrero JJ, Cabezas-Rodriguez I et al. Nonthyroidal illness: A risk factor for coronary calcification and arterial stiffness in patients undergoing peritoneal dialysis? J Intern Med 2013; 274: 584-593
168. Meuwese CL, Dekkers OM, Stenvinkel P et al. Nonthyroidal illness and the cardiorenal syndrome. Nat Rev Nephrol 2013; 9: 599-609
169. Koo HM, Kim CH, Doh FM et al. The impact of low triiodothyronine levels on mortality is mediated by malnutrition and cardiac dysfunction in incident hemodialysis patients. Eur J Endocrinol 2013; 169: 409-419
170. Ozen KP, Asci G, Gungor O et al. Nutritional state alters the association between free triiodothyronine levels and mortality in hemodialysis patients. Am J Nephrol 2011; 33: 305-312
171. Kovesdy CP, Kalantar-Zadeh K. Why is protein-energy wasting associated with mortality in chronic kidney disease? Semin Nephrol 2009; 29: 3-14
172. U.S. Renal Data System. USRDS 2012 annual data report: Atlas of endstage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2012
173. Biondi B, Fazio S, Palmieri EA et al. Left ventricular diastolic dysfunction in patients with subclinical hypothyroidism. J Clin Endocrinol Metab 1999; 84: 2064-2067
174. Monzani F, Caraccio N, Kozakowa M et al. Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: A double-blind, placebo-controlled study. J Clin Endocrinol Metab 2004; 89: 2099-2106
175. Monzani F, Di Bello V, Caraccio N et al. Effect of levothyroxine on cardiac function and structure in subclinical hypothyroidism: A double blind, placebo-controlled study. J Clin Endocrinol Metab 2001; 86: 1110-1115
176. Owen PJ, Rajiv C, Vinereanu D et al. Subclinical hypothyroidism, arterial stiffness, and myocardial reserve. J Clin Endocrinol Metab 2006; 91: 2126-2132
177. Razvi S,Weaver JU, Butler TJ et al. Levothyroxine teatment of subclinical hypothyroidism, fatal and nonfatal cardiovascular events, and mortality. Arch Intern Med 2012; 172: 811-817
178. Bommer C, Werle E, Walter-Sack I et al. D-thyroxine reduces lipoprotein( a) serum concentration in dialysis patients. J Am Soc Nephrol 1998; 9: 90-96
179. Shin DH, Lee MJ, Lee HS et al. Thyroid hormone replacement therapy attenuates the decline of renal function in chronic kidney disease patients with subclinical hypothyroidism. Thyroid 2013; 23: 654-661
180. Kalantar-Zadeh K, Kilpatrick RD, Kuwae N et al. Revisiting mortality predictability of serum albumin in the dialysis population: time dependency, longitudinal changes and population-attributable fraction. Nephrol Dial Transpl 2005; 20: 1880-1888
181. Lacson E, Jr, Ikizler TA, Lazarus JM et al. Potential impact of nutritional intervention on end-stage renal disease hospitalization, death, and treatment costs. J Ren Nutr 2007; 17: 363-371
182. Klein IL, Danzi S. The cardiovascular system in hypothyroidism. In: Braverman LE, Cooper DS (eds). Werner and Ingbar's the Thyroid. 10th edn. Philadelphia, PA: Lippincott Williams and Wilkins, 2013, pp. 575-582
183. Keating FR, Jr, Parkin TW, Selby JB et al. Treatment of heart disease associated with myxedema. Prog Cardiovas Dis 1961; 3: 364-381
184. Ladenson PW, Kristensen JD, Ridgway EC et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med 2010; 362: 906-916
185. Tatar E, Kircelli F, Ok E. The contribution of thyroid dysfunction on cardiovascular disease in patients with chronic kidney disease. Atherosclerosis 2013; 227: 26-31
186. Usvyat LA, Raimann JG, Carter M et al. Relation between trends in body temperature and outcome in incident hemodialysis patients. Nephrol Dial Transpl 2012; 27: 3255-3263
187. van Eps C, Hawley C, Jeffries J et al. Changes in serum prolactin, sex hormones and thyroid function with alternate nightly nocturnal home haemodialysis. Nephrology 2012; 17: 42-47
188. Fernandez-Reyes MJ, Diez JJ, Collado A et al. Are low concentrations of serum triiodothyronine a good marker for long-term mortality in hemodialysis patients? Clin Nephrol 2010; 73: 238-240
189. Lin YC, Chen TW, Yang WC et al. Abnormal thyroid function predicts mortality in patients receiving long-term peritoneal dialysis: A casecontrolled longitudinal study. J Chin Med Assoc 2012; 75: 54-59